{"entity":{"id":"papmet","kind":"trial","name":"PAPMET (SWOG S1500)","aka":["PAPMET","S1500","SWOG S1500"],"tldr":"PAPMET was the first randomised trial dedicated to papillary kidney cancer; cabozantinib held the disease back for longer than sunitinib, the previous default, while two more selective MET inhibitors did not.","summary":"Papillary renal cell carcinoma had been treated with drugs developed for clear cell disease. PAPMET, a SWOG-led randomised phase 2 trial, assigned 152 patients with metastatic papillary renal cell carcinoma, untreated or after one prior therapy, to sunitinib or to one of three MET-directed inhibitors: cabozantinib, crizotinib or savolitinib. The primary endpoint was progression-free survival against sunitinib.\n\nThe crizotinib and savolitinib arms were closed early for futility. Cabozantinib lengthened progression-free survival and produced more responses than sunitinib, and became the preferred single agent for papillary disease in guidelines, later joined by immunotherapy combinations tested in single-arm studies.","status":"positive","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT02761057","url":"https://clinicaltrials.gov/study/NCT02761057"}],"tags":["subtype-trials"],"related":[],"cancers":["papillary-rcc","rcc"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["cabozantinib","sunitinib","crizotinib","savolitinib"],"companies":["exelixis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["sumanta-pal"],"bottlenecks":[],"keyPapers":["paper-papmet-pal-lancet-2021"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02761057","phase":"2","setting":"Metastatic papillary renal cell carcinoma: sunitinib against cabozantinib, crizotinib or savolitinib","sponsor":"SWOG Cancer Research Network (National Cancer Institute)","result":"Cabozantinib lengthened progression-free survival compared with sunitinib in metastatic papillary renal cell carcinoma; the crizotinib and savolitinib arms closed for futility.","started":"2016-07-25","startedType":"actual","yearReported":2021,"enrolled":152,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Cabozantinib","n":44,"value":9},{"name":"Sunitinib","n":46,"value":5.6}],"hr":0.6,"ci":[0.37,0.97],"p":"0.019 (one-sided)","source":"https://doi.org/10.1016/S0140-6736(21)00152-5"},{"endpoint":"Response rate","unit":"%","arms":[{"name":"Cabozantinib","n":44,"value":23},{"name":"Sunitinib","n":46,"value":4}],"p":"0.010","source":"https://doi.org/10.1016/S0140-6736(21)00152-5"}]},"route":"/trials/papmet/","neighbours":{"cancer":[{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"},{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/"},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"company":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"}],"person":[{"id":"sumanta-pal","kind":"person","name":"Sumanta K. Pal","route":"/people/sumanta-pal/"}],"paper":[{"id":"paper-papmet-pal-lancet-2021","kind":"paper","name":"PAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma","route":"/key-papers/paper-papmet-pal-lancet-2021/"}]}}